

Jacob P Laubach

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1228112/jacob-p-laubach-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163
papers

6,880
citations

36
h-index

81
g-index

173
ext. papers

8,262
ext. citations

5.8
avg. IF

5.44
L-index

#	Paper	IF	Citations
163	Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 4082-4082	2.2	
162	A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Low Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1659-1659	2.2	
161	B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 4782-4782	2.2	
160	A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41). <i>Blood</i> , 2021 , 138, 4776-4776	2.2	0
159	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. <i>Nature Cell Biology</i> , 2021 , 23, 1199-1211	23.4	1
158	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021 , 22, e105-e118	21.7	32
157	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 12082-12082	2.2	
156	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021 , 35, 3526-3533	10.7	5
155	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 752-765	2	1
154	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology, The</i> , 2021 , 22, 142-154	21.7	22
153	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 757-767	2.2	43
152	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021 , 39, 565-575	2.2	40
151	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins. <i>Cell Reports</i> , 2021 , 34, 108532	10.6	15
150	Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 20	7	6
149	Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 1078155221995885	1.7	0
148	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2430-2442	2.2	18
147	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in -Mutated Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021 , 27, 6432-6444	12.9	3

146	A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). <i>American Journal of Hematology</i> , 2021 , 96, 1595-1603	7.1	6
145	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 149	7	1
144	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020 , 11, 2996	17.4	34
143	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2020 , 7, e370-e380	14.6	98
142	Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , 2020 , 1, 94-102	0.9	6
141	Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 25-26	2.2	0
140	Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study. <i>Blood</i> , 2020 , 136, 15-16	2.2	
139	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. <i>Blood</i> , 2020 , 136, 45-46	2.2	13
138	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. <i>Blood</i> , 2020 , 136, 4-6	2.2	1
137	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2380-2389	2.2	46
136	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , 2020 , 7, e447-e455	14.6	32
135	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 344-353	12.9	39
134	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 797-803	2	3
133	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. <i>Haematologica</i> , 2020 , 105, 468-477	6.6	27
132	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019 , 94, 1244-1253	7.1	24
131	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019 , 186, e35-e39	4.5	10
130	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 118-123	1.9	12
129	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba. <i>Blood</i> , 2019 , 134, 1906-1906	2.2	4

128	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. <i>Blood</i> , 2019 , 134, 691-691	2.2	31
127	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2019 , 134, 3169-3169	2.2	5
126	Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma. <i>Blood</i> , 2019 , 134, 3178-3178	2.2	8
125	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety. <i>Blood</i> , 2019 , 134, 1898-1898	2.2	4
124	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degradors of Oncoproteins. <i>Blood</i> , 2019 , 134, 3183-3183	2.2	7
123	Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy. <i>Blood</i> , 2019 , 134, 3091-3091	2.2	
122	Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 486-489	3.6	19
121	Evaluating the adverse effects of melphalan formulations. <i>Journal of Oncology Pharmacy Practice</i> , 2019 , 25, 1631-1637	1.7	6
120	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019 , 25, 478-486	12.9	19
119	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. <i>British Journal of Haematology</i> , 2018 , 180, 821-830	4.5	23
118	Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 942-945	4.4	19
117	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. <i>Leukemia</i> , 2018 , 32, 1838-1841	10.7	24
116	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , 2018 , 32, 2032-2036	10.7	7
115	74-Year-old female with new monoclonal protein on serum immunofixation electrophoresis. <i>Clinical Biochemistry</i> , 2018 , 51, 97-100	3.5	2
114	Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 180, 271-275	4.5	16
113	Maintenance and continuous therapy for multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 751-764	3.5	9
112	Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis. <i>JAMA Cardiology</i> , 2018 , 3, 865-870	16.2	34
111	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 182, 222-230	4.5	70

110	Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 181, 433-446	4.5	25
109	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018 , 132, 749-749	2.2	6
108	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018 , 132, 804-804	2.2	14
107	Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen. <i>Blood</i> , 2018 , 132, 3234-3234	2.2	
106	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3263-3263	2.2	
105	Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule. <i>Blood</i> , 2018 , 132, 2024-2024	2.2	
104	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. <i>Blood</i> , 2018 , 132, 1981-1981	2.2	0
103	CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias. <i>Blood</i> , 2018 , 132, 1367-1367	2.2	
102	Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs. <i>Blood</i> , 2018 , 132, 2235-2235	2.2	
101	A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. <i>British Journal of Haematology</i> , 2018 , 180, 41-51	4.5	41
100	Practical Considerations for Antibodies in Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 667-674	7.1	5
99	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018 , 8, 109	7	97
98	The power of proteasome inhibition in multiple myeloma. <i>Expert Review of Proteomics</i> , 2018 , 15, 1033-1052	4.2	25
97	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1949-1968	4.8	32
96	Elotuzumab monotherapy in patients with smoldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , 2018 , 182, 495-503	4.5	23
95	Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , 2017 , 10, 229-237	2.8	24
94	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 547-560	4.5	38
93	Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 756-763	4.5	14

92	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017 , 92, 746-751	7.1	21
91	The proteasome and proteasome inhibitors in multiple myeloma. <i>Cancer and Metastasis Reviews</i> , 2017 , 36, 561-584	9.6	150
90	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , 2017 , 117, 185-191	10.2	19
89	Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. <i>JAMA Oncology</i> , 2017 , 3, 980-988	13.4	53
88	Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 1800-1805	6.4	45
87	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. <i>Blood</i> , 2017 , 130, 902-902	2.2	3
86	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 35-48	3.8	19
85	Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2122-2122	2.2	1
84	Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. <i>Blood</i> , 2016 , 128, 246-246	2.2	26
83	Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. <i>Blood</i> , 2016 , 128, 3326-3326	2.2	6
82	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2016 , 128, 976-976	2.2	13
81	Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8014-8014	2.2	6
80	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. <i>Blood</i> , 2016 , 128, 3276-3276	2.2	
79	Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016 , 128, 2134-2134	2.2	
78	A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study. <i>Blood</i> , 2016 , 128, 2117-2117	2.2	0
77	A Pilot Study of Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2016 , 128, 5815-5815	2.2	
76	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2016 , 128, 1821-1828	2.2	82
75	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016 , 374, 1621-34	59.2	684

74	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016 , 127, 681-95	2.2	154
73	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. <i>Blood</i> , 2016 , 127, 2693-700	2.2	57
72	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016 , 127, 2833-40	2.2	182
71	Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016 , 169, 145-167	3.5	6
70	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015 , 21, 4607-18	12.9	214
69	CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. <i>Clinical Cancer Research</i> , 2015 , 21, 2660-2	12.9	36
68	Ibrutinib in previously treated Waldenström's macroglobulinemia. <i>New England Journal of Medicine</i> , 2015 , 372, 1430-40	59.2	617
67	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , 2015 , 11, 1153-68	3.6	23
66	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. <i>British Journal of Haematology</i> , 2015 , 169, 843-50	4.5	42
65	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015 , 373, 1207-19	59.2	761
64	Panobinostat for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015 , 21, 4767-73	12.9	150
63	Resolving the daratumumab interference with blood compatibility testing. <i>Transfusion</i> , 2015 , 55, 1545-54.	4.9	158
62	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. <i>British Journal of Haematology</i> , 2015 , 169, 851-8	4.5	44
61	The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 37	22.4	9
60	Management of relapsed multiple myeloma after autologous stem cell transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 793-8	4.7	19
59	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , 2015 , 126, 3036-3036	2.2	10
58	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4217-4217	2.2	7
57	Novel targeted agents in the treatment of multiple myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 903-25	3.1	14

56	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. <i>Blood</i> , 2014 , 123, 4136-42	2.2	102
55	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 1089-1108	1.1	
54	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 255-61	3.1	20
53	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , 2014 , 15, 1503-1512	21.7	207
52	Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 3955-61	12.9	27
51	Current strategies for treatment of relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2014 , 7, 97-111	2.8	58
50	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 255-261	3.1	14
49	An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 2140-2140	2.2	3
48	Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2014 , 124, 3081-3081	2.2	3
47	Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 84-84	2.2	25
46	Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8513-8513	2.2	17
45	MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8589-8589	2.2	4
44	Resistance to Proteasome Inhibitors in Multiple Myeloma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2014 , 47-80	0.3	3
43	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 5777-5777	2.2	2
42	Mimicking Myeloma Niche Ex Vivo. <i>Blood</i> , 2014 , 124, 2076-2076	2.2	
41	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. <i>Blood</i> , 2014 , 124, 3404-3404	2.2	
40	Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 27-27	2.2	1
39	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. <i>Blood</i> , 2014 , 124, 2070-2070	2.2	

38	Clinical translation in multiple myeloma: from bench to bedside. <i>Seminars in Oncology</i> , 2013 , 40, 549-53	5.5	7
37	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. <i>Blood</i> , 2013 , 121, 1961-7	2.2	132
36	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1947-1947	2.2	4
35	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013 , 122, 1969-1969	2.2	11
34	A Prospective Multicenter Study Of The Bruton Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2013 , 122, 251-251	2.2	29
33	Molecular Analysis Of Circulating Tumor Cells Identifies Mutations That Are Distinct From Those Present In The Bone Marrow Of Patients With Multiple Myeloma. <i>Blood</i> , 2013 , 122, 533-533	2.2	1
32	Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8512-8512	2.2	15
31	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8584-8584 ^{2.2}	2.2	2
30	Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8602-8602	2.2	
29	Management of myeloma-associated renal dysfunction in the era of novel therapies. <i>Expert Review of Hematology</i> , 2012 , 5, 51-66; quiz 67-8	2.8	25
28	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. <i>Leukemia</i> , 2012 , 26, 149-57	10.7	580
27	New proteasome inhibitors in myeloma. <i>Current Hematologic Malignancy Reports</i> , 2012 , 7, 258-66	4.4	74
26	Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study. <i>Blood</i> , 2012 , 120, 336-336	2.2	6
25	Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment. <i>Blood</i> , 2012 , 120, 565-565	2.2	
24	Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 1812-1812	2.2	
23	Multiple myeloma. <i>Annual Review of Medicine</i> , 2011 , 62, 249-64	17.4	99
22	Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. <i>Expert Review of Hematology</i> , 2011 , 4, 51-60	2.8	21
21	Management of relapsed and relapsed/refractory multiple myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 1209-16	7.3	20

20	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. <i>Blood</i> , 2011 , 117, 4409-19	2.2	125
19	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. <i>Blood</i> , 2011 , 118, 535-43	2.2	70
18	Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4243-9	2.2	107
17	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011 , 118, 1874-1874	2.2	1
16	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2011 , 118, 302-302	2.2	22
15	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. <i>Blood</i> , 2011 , 118, 3966-3966	2.2	1
14	Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial. <i>Blood</i> , 2011 , 118, 480-480	2.2	15
13	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. <i>Blood</i> , 2011 , 118, 815-815	2.2	
12	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011 , 118, 4134-4134	2.2	
11	The evolution and impact of therapy in multiple myeloma. <i>Medical Oncology</i> , 2010 , 27 Suppl 1, S1-6	3.7	32
10	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor Microenvironment Interactions.. <i>Blood</i> , 2010 , 116, 1574-1574	2.2	2
9	Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function. <i>Blood</i> , 2010 , 116, 451-451	2.2	
8	Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications. <i>Blood</i> , 2010 , 116, 5016-5016	2.2	
7	Novel therapies in the treatment of multiple myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 947-60	7.3	28
6	Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenström's Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 694-702	1.9	26
5	Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. <i>Seminars in Hematology</i> , 2009 , 46, 166-75	4	52
4	Bortezomib in the management of multiple myeloma. <i>Cancer Management and Research</i> , 2009 , 1, 107-173.6		5
3	Lack of Response to Vaccination in MGUS and Stable Myeloma.. <i>Blood</i> , 2009 , 114, 1852-1852	2.2	3

2 Maximizing the clinical benefit of novel therapies in multiple myeloma. *Oncology*, **2009**, 23, 415-6, 419 1.8

1 Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. *Blood*, **2008**, 112, 3696-3696 2.2 10